Argireline vs SNAP-8

Side by side

Argireline Medium and SNAP-8 Low are the two best-known "topical Botox" peptides ¹. The table is read from our encyclopedia entries.

One sequence, two lengths

Both peptides are copied from the start of SNAP-25, a protein nerve endings need to release acetylcholine, the signal that tells a muscle to contract. Argireline is six amino acids, Glu-Glu-Met-Gln-Arg-Arg, capped at both ends. SNAP-8 is the same six with Ala-Asp added, eight in all ¹. The idea behind both is the same: a decoy fragment that competes with the real protein and loosens the complex that releases acetylcholine, so expression muscles contract a little less and the lines they make soften.

Argireline's developers showed in 2002 that it interfered with that complex and inhibited neurotransmitter release in the laboratory, with far less effect than botulinum toxin (laboratory and volunteer study) ². We found no peer-reviewed paper that measures SNAP-8's effect on the complex, or compares it with Argireline; the "more potent" description comes from the supplier.

What Argireline has shown in people

In the 2002 developer study, an emulsion with 10% Argireline applied to healthy women reduced wrinkle depth by up to 30% after 30 days, measured by skin topography (volunteer study) ². A 2013 randomised placebo-controlled trial in 60 Chinese adults applied Argireline or placebo around the eyes twice daily for four weeks; global improvement was rated at 48.9% with Argireline against 0% with placebo, and roughness measurements fell only in the active group (randomised trial) ³.

A small medical trial tested it in blepharospasm, an involuntary eyelid spasm treated with botulinum toxin injections. In 24 patients, daily topical Argireline alongside the injections showed a non-significant trend toward longer symptom control, 3.7 against 3.0 months (randomised pilot) ⁴. In a 2023 three-arm trial in 21 women it did less well than a palmitoyl pentapeptide-4 cream (randomised trial) ⁵. These are small studies over weeks, most of them on cosmetic endpoints.

What SNAP-8 has shown in people

Every human study of SNAP-8 we found tested it inside a mixture. In a 2024 study, 24 people wore a microneedle patch containing acetyl octapeptide-3, a vitamin C derivative and a lipid signalling compound under one eye and a plain hyaluronic acid patch under the other, overnight, for 28 days; the active side showed more wrinkle improvement (controlled study of a combination) ⁶. In a 2020 single-centre 12-week study, a hyaluronic acid microneedle patch carrying SNAP-8 with four other actives reduced fine lines by 25.8% from baseline, with no control group (uncontrolled study of a combination) ⁷.

Neither study can say what SNAP-8 contributed, because it was never tested alone, and both delivered it through microneedles that pierce the skin's outer layer rather than in a cream. So the claim that SNAP-8 outperforms Argireline has no published trial behind it.

The problem both share: getting through the skin

A nerve ending sits well below the skin surface, and these peptides are water-loving molecules facing an oily barrier. In a diffusion study using human cadaver skin and a 10% Argireline emulsion, most of the peptide washed off the surface; what entered stayed mostly in the outer layer (0.22% of the dose in human skin), about 0.01% reached the epidermis, and none was detected in the dermis (laboratory study) ⁸. A 2025 review concluded that whether Argireline reaches neuromuscular junctions remains uncertain (review) ⁹.

SNAP-8 is larger, 1,075 against 889 g/mol, and carries an extra charged residue, the aspartate ¹. Larger and more charged generally means harder to push through skin, not easier. That has not been measured directly for SNAP-8, but it is the opposite of what "super" implies.

Safety and status

Both are cosmetic ingredients in the US, which do not need FDA approval and are not reviewed for effectiveness ¹⁰. The US Cosmetic Ingredient Review panel concluded in 2025 that Argireline is safe in cosmetics at concentrations up to 0.005% and that the data are insufficient to judge it above that (safety assessment) ¹¹; we found no equivalent review of SNAP-8. Note the gap: the 2002 study used 10%, two thousand times the level the panel was prepared to call safe. Injecting Argireline, which some sellers promote, has caused harm: a 2021 case report describes a Mycobacterium abscessus skin infection after facial injections (case report) ¹².

Our Argireline vs Botox article covers how far either peptide is from the effect of a toxin injection.

Questions to ask before you buy

• Does the label say how much peptide is in it? The tested concentrations range from trace amounts to 10%.
• Is there a trial of SNAP-8 alone, or only of mixtures?
• Is the product delivered in a cream or through microneedles? The SNAP-8 data are microneedle data.
• If injection is being suggested, why, when no study supports it?

How the differences add up (as of October 4, 2026)

Argireline has a small but real body of human evidence: a developer study, a 60-person randomised trial and a medical pilot, all showing modest effects, plus evidence that very little of it gets past the skin surface. SNAP-8 is a longer version of the same sequence with no published trial of its own, only two multi-ingredient microneedle studies. The claim that it works better is not supported by any published comparison.

Frequently asked questions

Is SNAP-8 better than Argireline?

No published study has compared them. SNAP-8 has no trial of its own; Argireline has several small ones.

What is the difference between SNAP-8 and Argireline?

SNAP-8 is the Argireline sequence with two more amino acids, Ala-Asp, added to the end.

Does Argireline work like Botox?

It targets part of the same nerve-signalling machinery, but its effect in the lab is far weaker, and very little of a cream reaches the deeper skin.

What concentration of Argireline is safe?

The US Cosmetic Ingredient Review panel found it safe up to 0.005% and the data insufficient above that.

Should Argireline or SNAP-8 be injected?

No study supports injecting either, and a 2021 case report describes a serious skin infection after Argireline injections.

Related on Grey Peptides

• Argireline
• SNAP-8 (acetyl octapeptide-3)
• Matrixyl vs Argireline
• Argireline vs Botox

Sources

1. Grey Peptides dataset records for Argireline (acetyl hexapeptide-8, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, C34H60N14O12S, 888.98 g/mol; evidence level medium) and SNAP-8 (acetyl octapeptide-3, Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, C41H70N16O16S, 1075.2 g/mol; evidence level low); cosmetic ingredients in the US; read October 4, 2026.
2. Blanes-Mira, C., et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci, 24(5), 303-10. PMID: 18498523
3. Wang, Y., et al. (2013). The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol, 14(2), 147-53. PMID: 23417317
4. Lungu, C., et al. (2013). Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol, 20(3), 515-518. PMID: 23146065
5. Aruan, R. R., et al. (2023). Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol, 16(2), 37-43. PMID: 36909866
6. Shin, J. Y., et al. (2024). Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol, 36(4), 215-224. PMID: 39082657
7. Avcil, M., et al. (2020). Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol, 19(2), 328-337. PMID: 31134751
8. Kraeling, M. E., et al. (2015). In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol, 34(1), 46-52. PMID: 24754410
9. Zdrada-Nowak, J., et al. (2025). Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci, 26(12). PMID: 40565185
10. U.S. Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated. Read October 4, 2026. Source
11. Johnson, W., Jr., et al. (2025). Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol, 44(2_suppl), 54S-63S. PMID: 40673537
12. Chen, C. F., et al. (2021). Mycobacterium abscessus infection after facial injection of argireline: A case report. World J Clin Cases, 9(8), 1996-2000. PMID: 33748252

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.